Companies › IMUX
IMMUNIC (IMUX)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001280776 · EDGAR filings · Updated 2026-07-16
IMMUNIC (IMUX) has reported institutional ownership of 47.0%, with 75 institutional managers holding positions valued at $71.0M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-07-16 — SCHEDULE 13G/A filed
- 2026-07-14 — Current report (8-K) filed
- 2026-07-07 — Insider transaction reported (Form 4)
- 2026-07-07 — Insider transaction reported (Form 4)
- 2026-07-07 — Insider transaction reported (Form 4)
- 2026-07-07 — Insider transaction reported (Form 4)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, IMMUNIC has 75 institutional holders and institutional ownership of 47.0%.
Insider activity
Insiders reported 10 transactions (9 buys, 0 sells) across 7 reporting insiders, with a net reported value of $268.3K.
Data flags from SEC filings
Related companies
NOVABRIDGE BIOSCIENCES (NBP) · CARIBOU BIOSCIENCES INC (CRBU) · SNDL INC (SNDL) · SAGIMET BIOSCIENCES INC (SGMT) · AC IMMUNE SA (ACIU) · LEONABIO INC (LONA)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-16.